Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance

Novartis AGTrade
NEOS S&P 500 High Income ETFTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs NEOS S&P 500 High Income ETF — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while NEOS S&P 500 High Income ETF trades at $54.12. The key difference: Novartis AG pays a 3.02% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.

NVSSPYI
Market Cap
$298.18B
Sector
HealthIncome / Options Overlay
52-Week High
$168.62$54.19
52-Week Low
$119.31$47.98
Enterprise Value
$339.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

NEOS S&P 500 High Income ETF

SPYI trades at $54.18, up 0.39% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, offering monthly dividends. Recent news highlights its role in retirement income strategies, though some articles caution about yield sustainability.

The outlook hinges on volatility-driven income generation, with potential for steady returns if market conditions persist. Risks include declining volatility reducing payouts and principal erosion concerns. Investors should weigh the high yield against the strategy's dependency on options premiums.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About NEOS S&P 500 High Income ETF

SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.

Read more on SPYI